US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

BHVN

Biohaven (BHVN)

Biohaven Ltd

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:BHVN

1 2 3 4 5 6 7 8 9 10 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
03/03/2025	15:26	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:BHVN	Biohaven Ltd
03/03/2025	15:25	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NYSE:BHVN	Biohaven Ltd
03/03/2025	06:31	PR Newswire (US)	Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300	NYSE:BHVN	Biohaven Ltd
03/03/2025	06:30	PR Newswire (US)	Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results	NYSE:BHVN	Biohaven Ltd
11/02/2025	06:30	PR Newswire (US)	Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia	NYSE:BHVN	Biohaven Ltd
13/01/2025	10:15	PR Newswire (US)	Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Po	NYSE:BHVN	Biohaven Ltd
12/01/2025	19:04	GlobeNewswire Inc.	Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs	NYSE:BHVN	Biohaven Ltd
07/01/2025	16:54	PR Newswire (US)	Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference	NYSE:BHVN	Biohaven Ltd
16/12/2024	06:30	PR Newswire (US)	Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates	NYSE:BHVN	Biohaven Ltd
06/12/2024	06:30	PR Newswire (US)	Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting	NYSE:BHVN	Biohaven Ltd
25/11/2024	06:30	PR Newswire (US)	Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity	NYSE:BHVN	Biohaven Ltd
12/11/2024	15:11	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:BHVN	Biohaven Ltd
12/11/2024	15:05	PR Newswire (US)	Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments	NYSE:BHVN	Biohaven Ltd
02/10/2024	15:05	PR Newswire (US)	Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares	NYSE:BHVN	Biohaven Ltd
01/10/2024	15:06	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NYSE:BHVN	Biohaven Ltd
01/10/2024	05:00	PR Newswire (US)	Biohaven Announces Pricing of $250 Million Public Offering of Common Shares	NYSE:BHVN	Biohaven Ltd
30/09/2024	15:05	PR Newswire (US)	Biohaven Announces Proposed Public Offering of Common Shares	NYSE:BHVN	Biohaven Ltd
30/09/2024	06:30	PR Newswire (US)	Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine	NYSE:BHVN	Biohaven Ltd
24/09/2024	05:15	IH Market News	Visa Faces Monopoly Lawsuit; Meta Introduces Celebrity Voices for Chatbot; Stellantis on the Hunt for New CEO	NYSE:BHVN	Biohaven Ltd
23/09/2024	06:30	PR Newswire (US)	Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)	NYSE:BHVN	Biohaven Ltd
20/09/2024	18:09	PR Newswire (US)	Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia	NYSE:BHVN	Biohaven Ltd
16/08/2024	15:31	Edgar (US Regulatory)	Form 424B7 - Prospectus [Rule 424(b)(7)]	NYSE:BHVN	Biohaven Ltd
08/08/2024	15:05	PR Newswire (US)	Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments	NYSE:BHVN	Biohaven Ltd
29/05/2024	06:30	PR Newswire (US)	Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day	NYSE:BHVN	Biohaven Ltd
29/05/2024	06:15	PR Newswire (US)	Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors	NYSE:BHVN	Biohaven Ltd
09/05/2024	15:16	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NYSE:BHVN	Biohaven Ltd
09/05/2024	15:05	PR Newswire (US)	Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments	NYSE:BHVN	Biohaven Ltd
13/04/2024	08:00	PR Newswire (US)	Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates	NYSE:BHVN	Biohaven Ltd
29/02/2024	15:05	PR Newswire (US)	Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments	NYSE:BHVN	Biohaven Ltd
08/01/2024	06:30	PR Newswire (US)	Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncolo	NYSE:BHVN	Biohaven Ltd

Showing the most relevant articles for your search:NYSE:BHVN

1 2 3 4 5 6 7 8 9 10 Próxima >

Taruga Minerals

Saratoga Investment

D and Z Media Acquisition

Ambipar Participacoes e ... ON

AMC Entertainment

Antimatter.Finance Governance To

Timbercreek Financial

DJ US Health Care Equipm...

DJ US Select Health Care...

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones